KLT 1101
Alternative Names: KLT-1101Latest Information Update: 28 Dec 2020
At a glance
- Originator GenScript Biotech Corp; Kang Litai Pharmaceutical
- Developer Kang Litai Pharmaceutical
- Class Antineoplastics; Cytokines; Recombinant proteins
- Mechanism of Action Cytokine replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Dec 2020 Genscript Biotech Corporation and Kanglitai Pharmaceutical entered into a R&D agreement for the development of KLT 1101
- 25 Nov 2020 Preclinical trials in Solid tumours in China (unspecified route)
- 25 Oct 2020 China Food and Drug administration approves IND application for KLT 1101 in Solid tumour